Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find Clinical Trials & Studies

AHEAD - A3 A45

I'm Interested!

AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)

  • Sex at Birth: Any
  • Age: Adult (18 - 64), Older Adult (65+)
  • Accepting Healthy People: Yes
  • Type: Prevention
  • Trial Phase: Phase III
  • Conditions Being Studied: Brain and Nervous System, Healthy Volunteers

Study Purpose

The purpose of this study is to test whether an investigational drug, BAN2401 (lecanemab) can help reduce the risk of developing AD dementia. This study if for healthy volunteers without a diagnosis of dementia or Alzheimer's.

Who Can Participate

Age: 55-80 years old

Principal Investigator
Rajeet Shrestha MD
Department/Division
Neurology (Brain Health and Memory)

Locations

UH Foley ElderHealth Center
3619 Park East Drive
Beachwood OH, 44122

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

  • UH IRB: SITE00001237
  • StudyID: 2020-0178
  • ClinicalTrials.gov: NCT04468659
I'm Interested!

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422